Vascular endothelial growth factor inhibitors in malignant gliomas.
Glioblastomas are highly vascularized tumors. Treatment strategies targeting angiogenesis have demonstrated promising results in preclinical studies and clinical trials in patients with malignant gliomas. Anti-VEGF agents, either alone or in combination with chemotherapy, have been associated with reduction in vasogenic brain edema, and prolonged progression-free survival. Larger prospective clinical trials are needed to validate these results, and to assess the impact of these agents on overall survival. Unfortunately, antiangiogenic treatment inevitably fails in most patients. Further studies are needed to understand the molecular pathways that enable a tumor to evade antiangiogenic therapy.
Brastianos
Priscilla K
PK
Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA. pbrastianos@partners.org
Batchelor
Tracy T
TT
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000098:blood supply*; D002986:Clinical Trials as Topic; D005910:Glioma / Q000098:blood supply*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D015398:Signal Transduction; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D042442:Vascular Endothelial Growth Factors
Neurosurgery. 2004 Aug;55(2):426-32; discussion 432
15271251
J Clin Oncol. 2009 May 20;27(15):2542-52
19332720
Nature. 1994 Feb 10;367(6463):576-9
8107827
Cancer Res. 2001 Aug 15;61(16):6020-4
11507045
Nat Rev Cancer. 2007 Jun;7(6):475-85
17522716
Nat Rev Drug Discov. 2007 Apr;6(4):273-86
17396134
Science. 1999 Jun 18;284(5422):1994-8
10373119
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
17317837
Neuro Oncol. 2008 Jun;10(3):355-60
18436627
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
J Clin Oncol. 2009 Oct 1;27(28):4733-40
19720927
Cancer Res. 1996 Sep 15;56(18):4264-6
8797602
J Clin Oncol. 2007 Oct 20;25(30):4722-9
17947719
J Nucl Med. 2006 Mar;47(3):393-403
16513607
Cancer Res. 1995 Dec 15;55(24):6161-5
8521408
Cancer Res. 1994 Sep 1;54(17):4564-8
8062241
Science. 1997 Jul 4;277(5322):48-50
9229772
Oncogene. 1997 May 1;14(17):2005-13
9160879
J Magn Reson Imaging. 2007 Aug;26(2):235-49
17623889
Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31
8005794
Cancer Treat Res. 2004;117:169-90
15015561
Neuro Oncol. 2005 Oct;7(4):436-51
16212809
Cancer Res. 2002 Jul 15;62(14):4015-22
12124335
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):85-90
20137866
Cancer Cell. 2004 Dec;6(6):553-63
15607960
J Clin Oncol. 2010 Jun 10;28(17):2817-23
20458050
Lancet. 2006 Oct 14;368(9544):1329-38
17046465
Invest New Drugs. 2015 Feb;33(1):247-53
25388940
J Clin Oncol. 2007 Oct 20;25(30):4714-21
17947718
Cancer Res. 2006 Dec 15;66(24):11851-8
17178882
Methods Mol Biol. 2009;472:323-42
19107440
Nat Med. 2001 Sep;7(9):987-9
11533692
Cancer Cell. 2007 Jan;11(1):83-95
17222792
J Clin Oncol. 1990 Jul;8(7):1277-80
2358840
Science. 2005 Jan 7;307(5706):58-62
15637262
Cancer Cell. 2007 Jan;11(1):69-82
17222791
Nat Rev Cancer. 2008 Aug;8(8):592-603
18650835
Cancer Cell. 2004 Nov;6(5):507-16
15542434
Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94
18565358
Int J Cancer. 1999 Feb 19;84(1):10-8
9988225
Clin Cancer Res. 2005 Nov 15;11(22):8145-57
16299247
Cancer Res. 2006 Aug 15;66(16):7843-8
16912155
J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39
16783163
J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80
16959960
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1526-37
17234361
Nat Rev Cancer. 2006 Jul;6(7):521-34
16794635
J Clin Oncol. 2006 Jul 10;24(20):3293-8
16829653
Cancer Res. 2004 Jun 1;64(11):3731-6
15172975
Nature. 2006 Dec 21;444(7122):1083-7
17183323
Nature. 2000 Sep 14;407(6801):242-8
11001067
Nature. 2006 Dec 21;444(7122):1032-7
17183313
Nat Rev Neurosci. 2007 Aug;8(8):610-22
17643088
Cancer Res. 2007 Mar 15;67(6):2729-35
17363594
Cancer. 2010 Apr 1;116(7):1776-82
20143438
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8
12177445
N Engl J Med. 2008 May 8;358(19):2039-49
18463380
Cancer Res. 2000 Sep 1;60(17):4959-67
10987313
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Neurology. 2008 Mar 4;70(10):779-87
18316689
J Clin Oncol. 2009 Jun 20;27(18):2905-8
19451418
Lab Invest. 2000 Jun;80(6):837-49
10879735
Nature. 1992 Oct 29;359(6398):845-8
1279432
Neurology. 2006 Apr 25;66(8):1258-60
16636248
N Engl J Med. 2007 Jan 11;356(2):125-34
17215530
Cancer Res. 1991 Oct 15;51(20):5760-5
1717153
J Clin Oncol. 2010 Apr 10;28(11):1963-72
20231676
Mol Biol Cell. 1993 Jan;4(1):121-33
7680247
Br J Cancer. 2001 Dec 14;85(12):2010-6
11747347
Nat Med. 1997 Feb;3(2):177-82
9018236
J Clin Oncol. 2010 Apr 20;28(12):e188-9; author reply e190-2
20159801
J Neurooncol. 2006 Jul;78(3):281-93
16554966
Exp Cell Res. 2006 Mar 10;312(5):549-60
16336962
Blood. 2006 Apr 1;107(7):2774-6
16339405
Acta Neuropathol. 2005 Jan;109(1):93-108
15685439